NeoGenomics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
4,834.00
33,689.00
23,420.00
12,525.00
12,821.00
9,811
Total Accounts Receivable
18,653.00
20,475.00
48,943.00
55,512.00
60,427.00
76,919
Inventories
2,301.00
2,616.00
5,108.00
6,253.00
7,474.00
8,650
Other Current Assets
1,703.00
1,962.00
4,889.00
4,535.00
4,241.00
8,288
Total Current Assets
27,491.00
58,742.00
82,360.00
78,825.00
84,963.00
103,668
Net Property, Plant & Equipment
9,694.00
15,082.00
34,577.00
34,036.00
36,504.00
60,888
Intangible Assets
2,577.00
7,141.00
234,221.00
224,083.00
221,184.00
337,921
Other Assets
154.00
141.00
129.00
174.00
689.00
2,038
Total Assets
39,916.00
81,106.00
351,287.00
337,118.00
343,340.00
505,015
ST Debt & Current Portion LT Debt
7,068.00
3,224.00
14,003.00
8,733.00
8,989.00
Accounts Payable
4,177.00
6,294.00
12,464.00
16,782.00
10,450.00
Other Current Liabilities
3,078.00
5,105.00
13,591.00
12,598.00
15,626.00
Total Current Liabilities
14,323.00
14,623.00
40,058.00
38,113.00
35,065.00
Long-Term Debt
3,294.00
5,257.00
57,376.00
97,436.00
96,435.00
Deferred Taxes
588.00
821.00
15,741.00
14,973.00
6,307.00
Total Liabilities
18,205.00
20,701.00
113,175.00
150,522.00
137,807.00
Common Equity (Total)
21,711.00
60,405.00
209,510.00
163,723.00
172,918.00
Total Shareholders' Equity
21,711.00
60,405.00
238,112.00
186,596.00
205,533.00
Total Equity
21,711.00
60,405.00
238,112.00
186,596.00
205,533.00
Liabilities & Shareholders' Equity
39,916.00
81,106.00
351,287.00
337,118.00
343,340.00
Preferred Stock (Carrying Value)
-
-
28,602.00
22,873.00
32,615.00

About NeoGenomics

View Profile
Address
12701 Commonwealth Drive
Fort Myers Florida 33913
United States
Employees -
Website http://www.neogenomics.com
Updated 07/08/2019
NeoGenomics, Inc. provides cancer diagnostics and pharma services. It operates through a network of cancer focused testing laboratories to provide genetic and molecular testing services. It offers various testing services, including Cytogenetics, Fluorescence In-Situ Hybridization, Flow Cytometry, Immunohistochemistry, Molecular testing and Pathology consultation.